| scholarly article | Q13442814 |
| P2093 | author name string | Yun Zhou | |
| Wendi Liu | |||
| Xinqiang Han | |||
| P2860 | cites work | ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the [...] | Q22306349 |
| Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes | Q24308695 | ||
| SUMO-2/3 regulates topoisomerase II in mitosis | Q24672260 | ||
| Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management | Q26766063 | ||
| Chemotherapy-Induced Cardiotoxicity: Overview of the Roles of Oxidative Stress | Q26780547 | ||
| 5-fluorouracil induced cardiotoxicity: review of the literature | Q26823262 | ||
| The emerging issue of cardiac dysfunction induced by antineoplastic angiogenesis inhibitors | Q27011540 | ||
| Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity | Q27027354 | ||
| A Randomized Trial of Intensive versus Standard Blood-Pressure Control | Q27231406 | ||
| Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer | Q27824847 | ||
| Novel concepts in radiation-induced cardiovascular disease. | Q28071302 | ||
| Recent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic Drugs | Q28087776 | ||
| Chronic mechanical circulatory support for inotrope-dependent heart failure patients who are not transplant candidates: results of the INTrEPID Trial | Q28241346 | ||
| The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia | Q28271441 | ||
| Sunitinib versus interferon alfa in metastatic renal-cell carcinoma | Q28282757 | ||
| Sorafenib in advanced clear-cell renal-cell carcinoma | Q28282767 | ||
| Heterozygous knockout of neuregulin-1 gene in mice exacerbates doxorubicin-induced heart failure | Q46440272 | ||
| A comparison of cardiomyocyte cytotoxic mechanisms for 5-fluorouracil and its pro-drug capecitabine. | Q46865578 | ||
| Different patterns of gene expression of topoisomerase II isoforms in differentiated tissues during murine development | Q48444620 | ||
| Lipid peroxidation and possible hydroxyl radical formation stimulated by the self-reduction of a doxorubicin-iron (III) complex | Q48665120 | ||
| Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden. | Q50554120 | ||
| Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib. | Q53087417 | ||
| Characteristics and survival of patients with chemotherapy-induced cardiomyopathy undergoing heart transplantation. | Q53130994 | ||
| 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. | Q53243856 | ||
| Cardiotoxic effects of 5-fluorouracil in the guinea pig | Q53956285 | ||
| Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. | Q54055530 | ||
| FGF-2 protects cardiomyocytes from doxorubicin damage via protein kinase C-dependent effects on efflux transporters. | Q54454923 | ||
| HER2 and responsiveness of breast cancer to adjuvant chemotherapy. | Q54600960 | ||
| 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiol | Q57057529 | ||
| Breast cancer | Q57117791 | ||
| 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure | Q57629858 | ||
| The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin | Q44671550 | ||
| Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. | Q44741318 | ||
| Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines | Q44780572 | ||
| The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients. | Q45949164 | ||
| Asymptomatic cardiac disease following mediastinal irradiation | Q46242921 | ||
| Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy | Q46245837 | ||
| Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab | Q46325595 | ||
| Topoisomerase II Mediated DNA Double-Strand Breaks: Implications in Doxorubicin Cardiotoxicity and Prevention by Dexrazoxane | Q60638397 | ||
| Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane | Q64387817 | ||
| Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II | Q64390546 | ||
| Cardiac disturbances during the administration of taxol | Q68312231 | ||
| Comparison and reproducibility of visual echocardiographic and quantitative radionuclide left ventricular ejection fractions | Q71063985 | ||
| Radiation heart disease. Analysis of 16 young (aged 15 to 33 years) necropsy patients who received over 3,500 rads to the heart | Q71540373 | ||
| Selective effects of oxygen free radicals on excitation-contraction coupling in ventricular muscle. Implications for the mechanism of stunned myocardium | Q71785167 | ||
| Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy | Q73665478 | ||
| Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas | Q74082946 | ||
| Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study | Q80629215 | ||
| Long-term effects of radiation dose on inflammatory markers in atomic bomb survivors | Q81244539 | ||
| Fluoropyrimidine-associated cardiotoxicity: revisited | Q83524446 | ||
| High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis | Q84654555 | ||
| Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation | Q85063202 | ||
| Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens | Q28328148 | ||
| Risk factors for doxorubicin-induced congestive heart failure | Q28328220 | ||
| Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases | Q28330575 | ||
| Cancer treatment and survivorship statistics, 2014 | Q29617702 | ||
| Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress. | Q30492863 | ||
| Deaths: Final Data for 2013. | Q31048496 | ||
| Big data analytics to improve cardiovascular care: promise and challenges | Q31062479 | ||
| Radiation-induced cardiovascular diseases: is the epidemiologic evidence compatible with the radiobiologic data? | Q31088291 | ||
| Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer | Q33598660 | ||
| Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors | Q33828690 | ||
| Mitochondrial topoisomerase I (top1mt) is a novel limiting factor of doxorubicin cardiotoxicity | Q34203187 | ||
| Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia | Q34205638 | ||
| Paclitaxel accelerates spontaneous calcium oscillations in cardiomyocytes by interacting with NCS-1 and the InsP3R | Q34249003 | ||
| Identification of the molecular basis of doxorubicin-induced cardiotoxicity | Q34308627 | ||
| Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. | Q34429779 | ||
| Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies | Q34563378 | ||
| Chronic health conditions in adult survivors of childhood cancer | Q34573463 | ||
| Estimates of the cancer incidence and mortality in Europe in 2006. | Q34575047 | ||
| American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects | Q34580448 | ||
| 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contrib | Q34677347 | ||
| A new frontier: cardio-oncology | Q34737225 | ||
| Epidemiology of anthracycline cardiotoxicity in children and adults. | Q34753960 | ||
| Treatment of hypertension in patients 80 years of age or older | Q34766135 | ||
| Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab | Q34855776 | ||
| Projections of the cost of cancer care in the United States: 2010-2020. | Q35022830 | ||
| Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors. | Q35198387 | ||
| Classification of anticancer drugs—a new system based on therapeutic targets | Q35571242 | ||
| QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors. | Q35677270 | ||
| Doxorubicin cardiotoxicity and the control of iron metabolism: quinone-dependent and independent mechanisms. | Q35708054 | ||
| Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer | Q36024588 | ||
| Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinoma | Q36150570 | ||
| Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study | Q36207305 | ||
| ErbB2 overexpression upregulates antioxidant enzymes, reduces basal levels of reactive oxygen species, and protects against doxorubicin cardiotoxicity. | Q36339400 | ||
| Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition | Q36800953 | ||
| Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib | Q37098098 | ||
| Anthracycline associated cardiotoxicity in survivors of childhood cancer | Q37112428 | ||
| Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial | Q37129069 | ||
| Cardiotoxicity profile of trastuzumab | Q37165488 | ||
| Intricacies of bevacizumab-induced toxicities and their management | Q37406599 | ||
| Heart Disease and Cancer Deaths - Trends and Projections in the United States, 1969-2020. | Q37450583 | ||
| Radiation-related heart disease: current knowledge and future prospects | Q37542024 | ||
| Anti-angiogenic Therapy in Cancer: Downsides and New Pivots for Precision Medicine | Q37562355 | ||
| Mitochondrial turnover and aging of long-lived postmitotic cells: the mitochondrial-lysosomal axis theory of aging | Q37570507 | ||
| Ionizing radiation-induced metabolic oxidative stress and prolonged cell injury | Q37693239 | ||
| Cardiac side-effects of cancer chemotherapy | Q37732792 | ||
| Antihypertensive treatment and development of heart failure in hypertension: a Bayesian network meta-analysis of studies in patients with hypertension and high cardiovascular risk | Q37808083 | ||
| Radiation-induced heart disease | Q37982218 | ||
| Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors | Q38098693 | ||
| Cancer therapy-induced left ventricular dysfunction: interventions and prognosis | Q38174782 | ||
| Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy | Q38286128 | ||
| Role of topoisomerase IIbeta in the expression of developmentally regulated genes. | Q38310467 | ||
| Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors | Q38313896 | ||
| Cardiovascular pharmacogenetics: a promise for genomically-guided therapy and personalized medicine | Q38974781 | ||
| Direct Effects of Anti-Angiogenic Therapies on Tumor Cells: VEGF Signaling. | Q38978306 | ||
| Cardiovascular Toxic Effects of Targeted Cancer Therapies | Q38978969 | ||
| The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer | Q39028181 | ||
| Pathology of radiation-induced heart disease: a surgical and autopsy study of 27 cases | Q39463484 | ||
| 5-Fluorouracil-associated cardiotoxicity | Q39625425 | ||
| Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase | Q39889569 | ||
| A reassessment of cardiac toxicity associated with Taxol. | Q40623889 | ||
| The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update | Q40829851 | ||
| Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. | Q41009855 | ||
| Ionizing radiation accelerates aortic lesion formation in fat-fed mice via SOD-inhibitable processes | Q41671401 | ||
| Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation | Q41896006 | ||
| Prospective randomized study of the role of N-acetyl cysteine in reversing doxorubicin-induced cardiomyopathy. | Q42266130 | ||
| Cardiotoxicity Associated With High-Dose Cyclophosphamide Therapy | Q42268276 | ||
| Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer | Q42552019 | ||
| 5-fluorouracil: cause of a fatal myocardial infarction in combined radiochemotherapy? | Q42556420 | ||
| Cardiac complications and manifestations of chemotherapy for cancer | Q43434093 | ||
| Radiation coronary arteritis refractory to surgical and percutaneous revascularization culminating in orthotopic heart transplantation. | Q43716125 | ||
| Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer | Q43724447 | ||
| ErbB2 is essential in the prevention of dilated cardiomyopathy. | Q43976647 | ||
| Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil | Q44035791 | ||
| Congestive heart failure risk in patients with breast cancer treated with bevacizumab. | Q44082273 | ||
| Care processes and clinical outcomes of continuous outpatient support with inotropes (COSI) in patients with refractory endstage heart failure | Q44483674 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P304 | page(s) | 31 | |
| P577 | publication date | 2017-09-12 | |
| P1433 | published in | npj Precision Oncology | Q50817392 |
| P1476 | title | Precision cardio-oncology: understanding the cardiotoxicity of cancer therapy. | |
| P478 | volume | 1 |
| Q92433295 | Cancer Therapy-Related Cardiac Dysfunction: An Overview for the Clinician |
| Q91931433 | Clinical Features and Outcomes of Patients With Malignancy and Takotsubo Syndrome: Observations From the International Takotsubo Registry |
| Q61454605 | Heart failure in cancer: role of checkpoint inhibitors |
| Q90178740 | Increased C-reactive protein is associated with the severity of thoracic radiotherapy-induced cardiomyopathy |
| Q90461158 | MicroRNAs in Cancer Treatment-Induced Cardiotoxicity |
| Q100635607 | Network integration and modelling of dynamic drug responses at multi-omics levels |
| Q90018066 | PARP inhibitor-induced torsades de pointes in long QT syndrome: a case report |
| Q91890567 | Skeletal Muscle Dysfunction and Exercise Intolerance in Children Treated with Haematopoietic Stem Cell Transplant-A Pilot Feasibility Study |
| Q90178687 | Spontaneously occurring cardiovascular lesions in commonly used laboratory animals |
| Q92070099 | Therapy-induced cardiotoxicity in breast cancer patients: a well-known yet unresolved problem |
| Q90165282 | Use of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes in Preclinical Cancer Drug Cardiotoxicity Testing: A Scientific Statement From the American Heart Association |
Search more.